Predictive oncology announces $4.1 million registered direct offering priced at-the-market under nasdaq rules

Minneapolis, jan. 22, 2021 (globe newswire) -- predictive oncology inc. (nasdaq: poai) (“predictive oncology” or “the company”), a knowledge-driven company focused on applying artificial intelligence (“ai”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 3,414,970 shares of its common stock, at a purchase price of $1.20 per share, for gross proceeds of approximately $4.1 million in a registered direct offering priced at-the-market under nasdaq rules. predictive oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of approximately 1,707,485 shares of common stock. the closing of the offering is expected to occur on or about january 26, 2021, subject to the satisfaction of customary closing conditions.
POAI Ratings Summary
POAI Quant Ranking